Axa S.A. Cti Biopharma Corp Transaction History

Axa S.A.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$4.45 - $6.17 $71,200 - $98,720	-16,000 Reduced 48.34%	17,100 $102,000
Q3 2022 Feb 14, 2023	BUY	$5.36 - $7.43 $91,656 - $127,053	17,100 Added 106.88%	33,100 $192,000
Q3 2022 Nov 14, 2022	BUY	$5.36 - $7.43 $91,656 - $127,053	17,100 Added 106.88%	33,100 $193,000
Q2 2022 Feb 14, 2023	SELL	$3.55 - $6.27 $60,705 - $107,216	-17,100 Reduced 51.66%	16,000 $95,000
Q2 2022 Aug 15, 2022	BUY	$3.55 - $6.27 $56,800 - $100,320	16,000 New	16,000 $96,000
Q1 2019 May 14, 2019	SELL	$0.9 - $1.37 $24,660 - $37,538	-27,400 Closed	0 $0
Q4 2018 Feb 13, 2019	SELL	$0.73 - $2.19 $25,258 - $75,774	-34,600 Reduced 55.81%	27,400 $20,000
Q3 2018 Nov 08, 2018	SELL	$1.72 - $5.24 $74,820 - $227,940	-43,500 Reduced 41.23%	62,000 $134,000
Q2 2018 Aug 13, 2018	BUY	$3.81 - $5.26 $331,470 - $457,620	87,000 Added 470.27%	105,500 $525,000
Q1 2018 May 14, 2018	BUY	$2.7 - $4.06 $49,950 - $75,110	18,500 New	18,500 $72,000

Ticker CTIC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 114,385,000
Market Cap $1.04B
Description
CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients w...

Get notified when there are updates to the investment portfolio of Axa S.A., based on Form 13F filings with the SEC.

Stay updated on Axa S.A. with notifications on news.